The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx.
 
Joseph A. Sparano
Stock and Other Ownership Interests - Metastat
Consulting or Advisory Role - Adgero Biopharmaceuticals; AstraZeneca; Cardinal Health; Celgene; Celldex; Genentech/Roche; Juno Therapeutics; Lilly; Merrimack; Novartis; Pfizer; Prescient Therapeutics
Research Funding - Deciphera (Inst); Genentech/Roche (Inst); Merck (Inst); Merrimack (Inst); Novartis (Inst); Novartis (Inst); Prescient Therapeutics (Inst); Radius Health (Inst)
Travel, Accommodations, Expenses - Adgero Biopharmaceuticals; AstraZeneca; Menarini Silicon Biosystems; Myriad Genetics; Pfizer; Roche/Genentech
 
Robert James Gray
Research Funding - Abbvie; Agios; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Genomic Health; Genzyme; GlaxoSmithKline; Janssen-Ortho; Merck Sharp & Dohme; Novartis; Onyx; Pfizer; Sanofi; Sequenta; Syndax; Takeda
 
Della F. Makower
No Relationships to Disclose
 
Tracy G. Lively
No Relationships to Disclose
 
Thomas James Saphner
No Relationships to Disclose
 
Maccon M. Keane
No Relationships to Disclose
 
Henry Leonidas Gomez
No Relationships to Disclose
 
Pavan S. Reddy
Consulting or Advisory Role - Merck
Speakers' Bureau - Clovis Oncology; Lilly
 
Timothy F. Goggins
No Relationships to Disclose
 
Ingrid A. Mayer
Consulting or Advisory Role - AstraZeneca; Genentech; GlaxoSmithKline; Immunomedics; Lilly; Macrogenics; Novartis
Research Funding - Genentech (Inst); Novartis (Inst); Pfizer (Inst)
 
Deborah Toppmeyer
Employment - Novartis (I)
Leadership - Novartis (I)
Stock and Other Ownership Interests - Novartis (I)
Consulting or Advisory Role - Merck
 
Adam Brufsky
Consulting or Advisory Role - Agendia; Bayer; Bioarray Therapeutics; bioTheranostics; Celgene; Eisai; Genentech/Roche; Genomic Health; Lilly; Merck; Myriad Pharmaceuticals; NanoString Technologies; Novartis; Pfizer; Puma Biotechnology
 
Matthew P. Goetz
Consulting or Advisory Role - bioTheranostics; Eisai; Genomic Health; Lilly; Novartis
Research Funding - Lilly; Pfizer
Patents, Royalties, Other Intellectual Property - Methods and Materials for Assessing Chemotherapy Responsiveness and Treating Cancer; METHODS AND MATERIALS FOR USING BUTYRYLCHOLINESTERASES TO TREAT CANCER
 
Daniel F. Hayes
Stock and Other Ownership Interests - InBiomotion; OncImmune
Consulting or Advisory Role - Agendia; Cellworks; Cepheid; CVS Caremark Breast Cancer Expert Panel; Freenome
Research Funding - AstraZeneca (Inst); Lilly (Inst); Menarini Silicon Biosystems (Inst); Merrimack (Inst); Pfizer (Inst); Puma Biotechnology (Inst)
Patents, Royalties, Other Intellectual Property - Circulating Tumor Cell Capturing Techniques and Devices. Patent No.: US 8,951,484 B2. Date of Patent: Feb. 10, 2015. Applicant Proprietor: University of Michigan. Dr. Daniel F. Hayes is designated as inventor/co-inventor.; Diagnosis and Treatment of Breast Cancer. Patent No. US 8,790,878 B2. Date of Patent: Jul. 29, 2014. Applicant Proprietor: University of Michigan. Dr. Daniel F. Hayes is designated as inventor/co-inventor.; Royalties from licensed technology.; Title: A method for predicting progression free and overall survival at each follow-up timepoint during therapy of metastatic breast cancer patients using circulating tumor cells. Patent no. 05725638.0-1223-US2005008602.
Travel, Accommodations, Expenses - Menarini Silicon Biosystems
Other Relationship - Menarini
 
Elizabeth Claire Dees
Consulting or Advisory Role - Novartis (I)
Research Funding - Bayer; Cerulean Pharma; Genentech/Roche; H3 Biomedicine; Lilly; Merck; Meryx Pharmaceuticals; Novartis; Pfizer
 
Kathleen I. Pritchard
Honoraria - Amgen; Eisai; Genomic Health International; Myriad Genetics; Novartis; Pfizer; Roche
Consulting or Advisory Role - Amgen; Eisai; Genomic Health International; Myriad Genetics; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Amgen; Eisai; Genomic Health International; Myriad Genetics; Novartis; Pfizer; Roche
 
Charles E. Geyer
Consulting or Advisory Role - Celgene; HERON; Myriad Genetics
Research Funding - Merck
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech/Roche
 
John A. Olson
Stock and Other Ownership Interests - Core Prognostex, Inc.
Patents, Royalties, Other Intellectual Property - Device for Containing and Analyzing Surgically Excised Tissue and Related Methods US Patent No. 7,172,558 Date Issued 02/02/2007 Expression and Function of GPR64/ADGRG2 in Endocrine Systems and Methods to Target it Therapeutically US Patent Applicatio
 
Kathy S. Albain
Consulting or Advisory Role - Agendia; Genentech/Roche; Genentech/Roche; Genomic Health; Myriad Genetics; Novartis; Pfizer
Research Funding - Seattle Genetics; Seattle Genetics (Inst)
Other Relationship - Puma Biotechnology
 
George W. Sledge
Leadership - Syndax
Stock and Other Ownership Interests - Syndax
Consulting or Advisory Role - Radius Health; Symphogen; Synaffix; Syndax; Taiho Pharmaceutical
Research Funding - Genentech/Roche (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Radius Health; Taiho Pharmaceutical